Literature DB >> 35068219

Is COVID-19-associated cytokine storm distinct from non-COVID-19 secondary hemophagocytic lymphohistiocytosis?

Johnson M Liu1, Jeffrey Chi2.   

Abstract

Cytokine storm is an umbrella term that describes an inflammatory syndrome characterized by elevated levels of circulating cytokines and hyperactivation of innate and/or adaptive immune cells. One type of cytokine storm is hemophagocytic lymphohistiocytosis (HLH), which can be either primary or secondary. Severe COVID-19-associated pneumonia and acute respiratory distress syndrome (ARDS) can also lead to cytokine storm/cytokine release syndrome (CS/CRS) and, more rarely, meet criteria for the diagnosis of secondary HLH. Here, we review the immunobiology of primary and secondary HLH and examine whether COVID-19-associated CS/CRS can be discriminated from non-COVID-19 secondary HLH. Finally, we review differences in immunobiology between these different entities, which may inform both clinical diagnosis and treatment of patients.

Entities:  

Keywords:  COVID-19; Cytokines; hemophagocytic lymphohistiocytosis; immunobiology; immunology/microbiology/virology; inflammation

Mesh:

Substances:

Year:  2022        PMID: 35068219      PMCID: PMC8899343          DOI: 10.1177/15353702211068840

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  49 in total

Review 1.  Pathology and pathogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Authors:  Henok Kessete Afewerky
Journal:  Exp Biol Med (Maywood)       Date:  2020-07-07

Review 2.  Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules.

Authors:  Geneviève de Saint Basile; Gaël Ménasché; Alain Fischer
Journal:  Nat Rev Immunol       Date:  2010-07-16       Impact factor: 53.106

3.  Treatment of hemophagocytic lymphohistiocytosis in adults.

Authors:  Paul La Rosée
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2015

Review 4.  COVID-19: Antiviral agents and enzyme inhibitors/receptor blockers in development.

Authors:  Manasi P Jogalekar; Anurag Veerabathini; Ankit B Patel
Journal:  Exp Biol Med (Maywood)       Date:  2021-03-23

5.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.

Authors:  Ning Tang; Dengju Li; Xiong Wang; Ziyong Sun
Journal:  J Thromb Haemost       Date:  2020-03-13       Impact factor: 5.824

Review 6.  Cytokine Storm.

Authors:  David C Fajgenbaum; Carl H June
Journal:  N Engl J Med       Date:  2020-12-03       Impact factor: 91.245

7.  Hematologic parameters in patients with COVID-19 infection.

Authors:  Bingwen Eugene Fan; Vanessa Cui Lian Chong; Stephrene Seok Wei Chan; Gek Hsiang Lim; Kian Guan Eric Lim; Guat Bee Tan; Sharavan Sadasiv Mucheli; Ponnudurai Kuperan; Kiat Hoe Ong
Journal:  Am J Hematol       Date:  2020-03-19       Impact factor: 10.047

Review 8.  Targeting Bruton's Tyrosine Kinase in Inflammatory and Autoimmune Pathologies.

Authors:  Stefan F H Neys; Rudi W Hendriks; Odilia B J Corneth
Journal:  Front Cell Dev Biol       Date:  2021-06-04

9.  Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19.

Authors:  Yang Yang; Chenguang Shen; Jinxiu Li; Jing Yuan; Jinli Wei; Fengmin Huang; Fuxiang Wang; Guobao Li; Yanjie Li; Li Xing; Ling Peng; Minghui Yang; Mengli Cao; Haixia Zheng; Weibo Wu; Rongrong Zou; Delin Li; Zhixiang Xu; Haiyan Wang; Mingxia Zhang; Zheng Zhang; George F Gao; Chengyu Jiang; Lei Liu; Yingxia Liu
Journal:  J Allergy Clin Immunol       Date:  2020-04-29       Impact factor: 14.290

Review 10.  The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.

Authors:  Qing Ye; Bili Wang; Jianhua Mao
Journal:  J Infect       Date:  2020-04-10       Impact factor: 38.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.